Inflammatory Bowel Disease Treatment Market Size Report, 2034

Inflammatory Bowel Disease Treatment Market - By Treatment Type, By Drug Class, By Route of Administration, By Distribution Channel - Global Forecast, 2025 - 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Global

1.3.2&nbsp;&nbsp;&nbsp; Regional/country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional trends

2.2.2&nbsp;&nbsp;&nbsp; Treatment type trends

2.2.3&nbsp;&nbsp;&nbsp; Drug class trends

2.2.4&nbsp;&nbsp;&nbsp; Route of administration trends

2.2.5&nbsp;&nbsp;&nbsp; Distribution channel trends

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of IBD

3.2.1.2&nbsp;&nbsp;&nbsp; Technological advancements

3.2.1.3&nbsp;&nbsp;&nbsp; Favorable reimbursement policies

3.2.1.4&nbsp;&nbsp;&nbsp; Growing awareness and early diagnosis of IBD symptoms

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Stringent regulatory scenario

3.2.2.2&nbsp;&nbsp;&nbsp; High cost of treatment

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Rising adoption of biologics and targeted therapies

3.2.3.2&nbsp;&nbsp;&nbsp; Expansion in emerging markets

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.5.1&nbsp;&nbsp;&nbsp; U.S.

3.5.2&nbsp;&nbsp;&nbsp; Europe

3.5.3&nbsp;&nbsp;&nbsp; Asia Pacific

3.6&nbsp;&nbsp;&nbsp; Pipeline analysis

3.7&nbsp;&nbsp;&nbsp; Investment scenarios outlook

3.8&nbsp;&nbsp;&nbsp; Treatment switching patterns or sequencing trends

3.9&nbsp;&nbsp;&nbsp; Epidemiological scenario

3.10&nbsp;&nbsp;&nbsp; Future market trends/ Key marketed therapies

3.11&nbsp;&nbsp;&nbsp; Brand analysis, 2024

3.12&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.13&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.3.1&nbsp;&nbsp;&nbsp; Global

4.3.2&nbsp;&nbsp;&nbsp; North America

4.3.3&nbsp;&nbsp;&nbsp; Europe

4.3.4&nbsp;&nbsp;&nbsp; Asia Pacific

4.3.5&nbsp;&nbsp;&nbsp; Latin America

4.3.6&nbsp;&nbsp;&nbsp; MEA

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.6&nbsp;&nbsp;&nbsp; Key developments

4.6.1&nbsp;&nbsp;&nbsp; Mergers and acquisitions

4.6.2&nbsp;&nbsp;&nbsp; Partnerships and collaborations

4.6.3&nbsp;&nbsp;&nbsp; New product type launches

4.6.4&nbsp;&nbsp;&nbsp; Expansion plans

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Crohn&#39;s disease

5.3&nbsp;&nbsp;&nbsp; Ulcerative colitis

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; First-line treatment

6.2.1&nbsp;&nbsp;&nbsp; Aminosalicylates

6.2.2&nbsp;&nbsp;&nbsp; Corticosteroids

6.3&nbsp;&nbsp;&nbsp; Second-line treatment

6.3.1&nbsp;&nbsp;&nbsp; IL inhibitors

6.3.2&nbsp;&nbsp;&nbsp; TNF inhibitors

6.3.3&nbsp;&nbsp;&nbsp; JAK inhibitors

6.3.4&nbsp;&nbsp;&nbsp; Anti-integrin

6.3.5&nbsp;&nbsp;&nbsp; S1P receptor modulator

6.4&nbsp;&nbsp;&nbsp; Combination therapy

6.4.1&nbsp;&nbsp;&nbsp; TNF inhibitors + thiopurines

6.4.2&nbsp;&nbsp;&nbsp; Other combination therapies

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Injectable

7.3&nbsp;&nbsp;&nbsp; Oral

7.4&nbsp;&nbsp;&nbsp; Rectal

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospital pharmacy

8.3&nbsp;&nbsp;&nbsp; Retail pharmacy

8.4&nbsp;&nbsp;&nbsp; Online pharmacy

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Netherlands

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; AbbVie

10.2&nbsp;&nbsp;&nbsp; Alvotech

10.3&nbsp;&nbsp;&nbsp; Amgen

10.4&nbsp;&nbsp;&nbsp; Biogen

10.5&nbsp;&nbsp;&nbsp; Boehringer Ingelheim

10.6&nbsp;&nbsp;&nbsp; Celltrion

10.7&nbsp;&nbsp;&nbsp; Dr Falk Pharma

10.8&nbsp;&nbsp;&nbsp; Eli Lilly

10.9&nbsp;&nbsp;&nbsp; Ferring

10.10&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson

10.11&nbsp;&nbsp;&nbsp; ORGANON

10.12&nbsp;&nbsp;&nbsp; Pfizer

10.13&nbsp;&nbsp;&nbsp; Takeda Pharmaceuticals

10.14&nbsp;&nbsp;&nbsp; UCB

Inflammatory Bowel Disease Treatment Market

Get a free sample of this report